ETF Holdings Breakdown of ALT

Stock NameAltitude Group Plc
TickerALT(GBX) LSE
TYPECommon Stock
CountryUK
ISINGB00B0LSFV82
LEI213800VACSTYYSI39R89

News associated with ALT

Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT)
Rhumbline Advisers lowered its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 4.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,876 shares of the company’s stock after selling 4,343 shares during the quarter. Rhumbline Advisers’ holdings in Altimmune were worth […] - 2025-03-07 09:22:50
Altimmune, Inc. (NASDAQ:ALT) Stock Position Decreased by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC cut its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 53.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,197 shares of the company’s stock after selling 35,340 shares during the period. Los Angeles Capital Management […] - 2025-03-05 10:41:41
Altimmune (NASDAQ:ALT) Given “Buy” Rating at HC Wainwright
Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 101.34% from the stock’s previous close. A number of other research […] - 2025-03-05 06:56:51
Altimmune, Inc. (NASDAQ:ALT) Sees Large Decline in Short Interest
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 23,320,000 shares, a decrease of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the short-interest ratio is currently 7.3 […] - 2025-02-19 08:46:12
Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.83
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. […] - 2025-02-04 06:46:59

ALT institutional holdings

The following institutional investment holdings of ALT have been identified

Date ETF ISIN/Name Num Shares Book value
2025-03-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 41,589 -10.2%USD 230,819 -4.5%
2025-03-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 35,126USD 194,949 5.2%
2025-03-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 35,126USD 194,949 5.2%
2025-03-12 IE000T9EOCL3 (iS Wor ESG En Acc) 1,195USD 6,632 5.2%
Total =113,036 USD 627,349
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.